UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Leukemia, 2016-05, Vol.30 (5), p.1044-1054

2016

Volltextzugriff (PDF)

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

Leukemia, 2012-09, Vol.26 (9), p.2061-2068

2012

Volltextzugriff (PDF)

Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center

Leukemia, 2015-02, Vol.29 (2), p.312-320

2015

Volltextzugriff (PDF)

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Leukemia, 2012-10, Vol.26 (10), p.2197-2203

2012

Volltextzugriff (PDF)

MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications

Leukemia, 2008-06, Vol.22 (6), p.1095-1105

2008

Volltextzugriff (PDF)

Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy

Leukemia, 2014-04, Vol.28 (4), p.958-961

2014

Volltextzugriff (PDF)

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era

Leukemia, 2017-09, Vol.31 (9), p.1845-1854

2017

Volltextzugriff (PDF)

Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

Leukemia, 2012-06, Vol.26 (6), p.1189-1194

2012

Volltextzugriff (PDF)

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia

Leukemia, 2007-11, Vol.21 (11), p.2311-2315

2007

Volltextzugriff (PDF)

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase

Leukemia, 2012-05, Vol.26 (5), p.959-962

2012

Volltextzugriff (PDF)

Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

Leukemia, 2016-07, Vol.30 (7), p.1606-1609

2016

Volltextzugriff (PDF)

A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome

Leukemia, 2017-10, Vol.31 (10), p.2011-2019

2017

Volltextzugriff (PDF)

Moving toward individualized target-based therapies in acute myeloid leukemia

Annals of oncology, 2023-02, Vol.34 (2), p.141-151

2023

Volltextzugriff (PDF)

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

Leukemia, 2017-02, Vol.31 (2), p.318-324

2017

Volltextzugriff (PDF)

Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics

Leukemia, 2009-09, Vol.23 (9), p.1605-1613

2009

Volltextzugriff (PDF)

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history

Leukemia, 2010-01, Vol.24 (1), p.6-12

2010

Volltextzugriff (PDF)

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

Leukemia, 2010-07, Vol.24 (7), p.1299-1301

2010

Volltextzugriff (PDF)

Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome

Leukemia, 2016-02, Vol.30 (2), p.325-330

2016

Volltextzugriff (PDF)

Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia

Leukemia, 2013-06, Vol.27 (6), p.1411-1413

2013

Volltextzugriff (PDF)

Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primates

The pharmacogenomics journal, 2018-05, Vol.18 (3), p.436-443

2018

Volltextzugriff (PDF)

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Haematologica (Roma), 2015-09, Vol.100 (9), p.1139-1145

2015

Volltextzugriff (PDF)

Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy

Leukemia, 2003-06, Vol.17 (6), p.1100-1103

2003

Volltextzugriff (PDF)

Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications

Annals of internal medicine, 2001-04, Vol.134 (7), p.573

2001

Volltextzugriff (PDF)

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

Leukemia, 2011-12, Vol.25 (12), p.1808-1814

2011

Volltextzugriff (PDF)

Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors

Leukemia, 2017-07, Vol.31 (7), p.1654-1657

2017

Volltextzugriff (PDF)

1 – 25 von 1.611

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.556)
Mit Volltextzugriff
(1.448)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.611)

Erscheinungsjahr

n.n

Thema

Humans
(936)
Science & Technology
(899)
Life Sciences & Biomedicine
(896)
Biological And Medical Sciences
(602)
Medical Sciences
(597)
Middle Aged
(585)
Oncology
(554)
Adult
(531)
Female
(487)
Hematology
(487)
Male
(481)
Aged
(467)
Hematologic And Hematopoietic Diseases
(331)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(313)
Pharmacology. Drug Treatments
(271)
Prognosis
(251)
Antineoplastic Agents
(246)
Treatment Outcome
(216)
Adolescent
(204)
Aged, 80 And Over
(199)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications

Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era

Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase

Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome

Moving toward individualized target-based therapies in acute myeloid leukemia

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome

Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia

Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primates

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy

Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors

Suchergebnisse filtern